{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Count of participants with acute GVHD grades III-IV.","groups":[{"description":"Following total-body irradiation, thiotepa, fludarabine, and muromonab-CD3, participants are given a donor peripheral stem cell transplant and a donor natural killer cell transplant.","id":"OG000","title":"Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to day 100","title":"Risk of Developing Grades III-IV Acute Graft-vs-host Disease (GVHD)","type":"PRIMARY","unitOfMeasure":"Participants"}